Key Facts about Monoclonal Antibodies
Monoclonal antibodies (mAbs) are highly specific immunoglobulin molecules produced by identical immune cells derived from a single parent clone, making them a cornerstone of modern biotherapeutics in oncology, autoimmune and infectious diseases. Since the approval of the first therapeutic mAb in 1986, the field has grown into a multi-billion-USD market, with hundreds of antibody-based products approved or in clinical development worldwide.
The mAb production process is fundamentally a mammalian cell culture process. Cells used for mAb manufacturing secrete the antibody into the culture medium, where product quality is directly linked to the bioreactor environment. Critical quality attributes (CQAs) defined under cGMP guidance of the FDA and EMA — including aggregation, charge variants and glycosylation — must be tightly controlled across every stage of upstream manufacturing.
Because mAb-producing cells are shear-sensitive eukaryotic cells with complex post-translational modifications, they require gentle agitation, precise gas transfer and defined feeding strategies. This makes the choice of bioreactor system — from small-scale bioreactors for process development to single-use and stainless steel systems for commercial production — a critical driver of product titer, glycan profile and manufacturing efficiency.
Typical cell types used for monoclonal antibody production
The selection of the production cell line is one of the most important steps in the monoclonal antibody manufacturing process. While several mammalian cell lines are technically suitable, the industry has strongly converged on a small number of robust, regulatory-accepted host systems for mAb production.
-
Chinese hamster ovary (CHO) cells
(industry standard, >70% of recombinant biopharmaceuticals)
The dominant platform for mAb production, responsible for more than 70% of all recombinant biopharmaceuticals on the market. CHO cells grow well in suspension, perform human-like post-translational modifications (especially N-glycosylation) and tolerate chemically defined, animal-component-free media — making them well suited to large-scale fed-batch and perfusion processes.
-
NS0 and Sp2/0 mouse myeloma cells
(historical, hybridoma-based)
Historically used for hybridoma-based mAb production. They offer good secretion capacity but are less scalable and show a different glycosylation pattern than CHO, which is why most new therapeutic antibody programs favor CHO.
-
HEK293 cells
(human embryonic kidney)
Mainly used for transient mAb expression during early research, candidate screening and for antibodies that require fully human glycosylation patterns. Particularly valued in Fc-engineering and biophysical characterization workflows.
-
Hybridoma cells
(B-cell / myeloma fusion)
The original B-cell / myeloma fusion cells used to generate monoclonal antibodies. Still highly relevant for antibody discovery and research reagents, but rarely used for large-scale therapeutic mAb manufacturing due to limited scalability compared to CHO.
Key process parameters for mAb production
Monoclonal antibody production in CHO and other mammalian cells depends on the precise control of a small number of critical process parameters. These parameters directly determine cell growth, specific productivity (qP), volumetric titer and the critical quality attributes of the mAb, especially glycan profile and aggregate level.
-
pH control
(6.8–7.2)
Maintained via CO₂ sparging and base addition (e.g., sodium bicarbonate). Higher pH (~7.15) tends to favor cell density, whereas a controlled pH shift to ~6.85 during the production phase can increase mAb titer and reduce byproducts such as lactate.
-
Dissolved oxygen (DO)
(20–50%)
Regulated by gas mixing (air/O₂) and agitation. Too low DO leads to hypoxia and drops in productivity; too high DO can cause oxidative stress and affect glycosylation.
-
Temperature and temperature shift
(36–37 °C → 32–34 °C)
Many industrial mAb processes use a temperature shift during the production phase to slow growth (µ) and boost specific productivity, often increasing final titer by 20–25%.
-
Dissolved CO₂
(< 120–150 mmHg)
Elevated dissolved CO₂ in large-scale bioreactors is inhibitory for CHO cells and can alter mAb glycosylation. It is controlled via sparger design, agitation and sparge-gas strategy.
-
Osmolality and feed strategy
Glucose and glutamine feeds are designed to avoid lactate accumulation (typically < 30 mM) and ammonia buildup, both of which impair viability and product quality. Multi-stage feeds support intensified fed-batch titers > 10 g/L.
-
Shear and mixing
CHO and other mammalian cells are shear-sensitive. Low impeller speeds, marine or pitched-blade impellers and controlled bubble size (micro-sparging) protect viability while ensuring sufficient kLa for oxygen transfer.
-
Viable cell density (VCD) and viability
Key performance indicators monitored daily via off-line or at-line analytics; N-1 intensification can provide inoculum densities of 15–30 × 10⁶ cells/mL to shorten the production run by 2–3 days.
Standard process workflow for monoclonal antibody production
The standard monoclonal antibody manufacturing process follows a well-established upstream workflow that scales from early process development in small-scale bioreactors to commercial-scale mAb production. The main steps in a modern CHO-based platform are:
-
Antigen selection and cell line development
Identification of a disease-specific antigen, generation of a stable CHO cell line (e.g., via DHFR/MTX or GS/MSX selection) and isolation of high-producing monoclonal clones.
-
Clone screening and scale-down characterization
Top clones are evaluated in shake flasks and small-scale bioreactors (e.g., 250 mL – 2 L) for titer, growth, specific productivity and product quality (glycosylation, aggregation, charge variants).
-
Seed train and N-1 intensification
Expansion of the working cell bank through a series of cultures; N-1 perfusion can generate high-density inocula (3–5 × 10⁶ up to 30 × 10⁶ cells/mL) for high-inoculum fed-batch or perfusion processes.
-
Inoculation of the production bioreactor
Transfer into the production bioreactor at defined volume and density, with controlled pH, DO and temperature set points.
-
Production phase
Cascade control of pH, DO and temperature; bolus or continuous feeding; optional temperature shift to boost specific productivity; perfusion operation using cell retention devices such as acoustic separators (e.g., BioSep) or alternating tangential flow (ATF) for high-density processes.
-
Process monitoring and PAT
On-/at-line monitoring of viable cell density, titer, glucose, lactate, glutamine, ammonia and dissolved CO₂; product quality monitoring via HPLC and mass spectrometry.
-
Harvest and clarification
End-of-batch harvest or continuous harvest via cell retention, followed by clarification (depth filtration, centrifugation) to prepare the mAb for downstream purification (Protein A affinity, ion exchange, polishing).
Applikon bioreactor types for monoclonal antibody production
All Applikon bioreactor formats are designed as a scalable platform for monoclonal antibody production, from early process development to commercial-scale mAb manufacturing. Unified control strategies via Livit Flex and my-Control bioprocess controllers enable consistent pH, DO, temperature and feeding cascades across formats — supporting a true scale-up / scale-down approach with seamless transition from R&D to GMP.
| Type | Scale | Key Use Cases | mAb-Specific Features |
|---|---|---|---|
| Applikon MiniBio glass small-scale bioreactor | 250 mL – 1000 mL | mAb process development, clone screening, media and feed optimization, DoE scale-down | Low media consumption, shear-optimized setup for CHO, parallel operation, perfusion-ready for high-density N-1 studies |
| Applikon glass autoclavable bioreactors for mAb production | 2–20 L | R&D and pilot-scale fed-batch and perfusion runs, scale-up/scale-down models, feed and temperature-shift studies | Multi-gas sparging, multiple sensor options (pH, DO, CO₂, optical), flexible impeller configuration for shear-sensitive CHO cultures, perfusion-ready |
| AppliFlex ST single-use bioreactor for mAb manufacturing | 0.5–15 L | Flexible mAb clinical and small-scale GMP production, rapid campaign changeover, process optimization, scale-up/scale-down | 3D-printed customizable single-use vessels, pre-sterilized, reduced cross-contamination risk, fast setup for high-throughput mAb production, perfusion-ready |
| Stainless-steel bioreactors for large-scale mAb production and continuous perfusion | from 20 L to 5,000 L | Commercial-scale mAb manufacturing, repeated fed-batch and perfusion campaigns, platform biopharmaceutical production | CIP/SIP capability, robust shear control at large scale, scalable agitation and sparger design, perfusion-ready for intensified bioprocessing |
Why Choose the Applikon AppliFlex ST for mAB Manufacturing?
As a leading tool for mAB production, the AppliFlex ST allows you to dive straight into your bioprocess with quick setup and easy operation — reducing production times and costs while enhancing the overall efficiency of the mAB manufacturing process.
Detailed Process Guide for mAB Production
Optimizing monoclonal antibody production with Applikon bioreactors involves a series of carefully coordinated steps — from bioreactor and antigen selection through to cell expansion and cultivation under ideal conditions
The first step involves choosing the most suitable equipment based on the product and the goals of the bioprocess — options include batch, fed-batch, perfusion, or chemostat processes. Applikon bioreactors support all these process forms, ensuring maximum productivity and flexibility. Identifying and preparing the specific antigen that the monoclonal antibody will target involves finding a unique marker associated with the disease, enhancing the accuracy and efficiency of the produced antibodies.
Producing monoclonal antibodies primarily uses Chinese hamster ovary (CHO) cells as production organism. Advanced biotechnological techniques such as transcriptomics, proteomics, and methotrexate-based amplification are used to enhance the expression of genetic factors and significantly increase mAB productivity. CHO cells are extensively used due to their exceptional ability to perform complex post-translational modifications — crucial for the functional efficacy of therapeutic proteins. The hybridoma technology, which fuses B-cells with myeloma cells, is foundational but less scalable compared to CHO cell production, making CHO cells the preferred option for large-scale manufacturing.
Once the optimal cells are selected, expanding and cultivating them under ideal conditions is critical for high-quality mAB production with high yields. Applikon bioreactors provide precise control over temperature, pH, and dissolved oxygen levels — essential for maximizing cell growth and antibody yield. This optimized environment supports robust cell expansion and efficient antibody production, ensuring a consistent and reliable supply of mABs.
The Applikon AppliFlex ST single-use bioreactor stands out for its precision and control over environmental conditions, scalability across different volumes from process development to commercial-scale production, efficiency through quick setup and easy operation, and versatility thanks to customization options that support a wide range of cell types and cultivation strategies. The AppliFlex ST allows you to dive straight into your bioprocess, reducing production times and costs throughout the mAB manufacturing process.
